^
    1m
    Efficacy and Safety of Firsekibart versus Anakinra in Adult-Onset Still's Disease (ChiCTR2500109835)
    P4, N=20, Not yet recruiting, Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
    New P4 trial
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)
    2ms
    A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Ruijin Hospital
    New trial
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)
    8ms
    Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)
    9ms
    Clinical Study of Genakumab for Injection in Patients With Acute Gout (clinicaltrials.gov)
    P1/2, N=121, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)
    10ms
    A Bioequivalence Study of Two Different Dosage Form of Genakumab (clinicaltrials.gov)
    P1, N=178, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)
    11ms
    A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jin Beixin (firsekibart)
    11ms
    Gensci 048-202: A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) (clinicaltrials.gov)
    P2, N=165, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | N=106 --> 165 | Trial completion date: May 2024 --> Jan 2024
    Enrollment change • Trial completion date
    |
    Jin Beixin (firsekibart)
    1year
    Safety & Efficacy of Genakumab in Patients With Frequent Flares (clinicaltrials.gov)
    P3, N=302, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2024 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Jin Beixin (firsekibart)
    1year
    Gensci 048-202: Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> May 2024
    Trial completion • Trial completion date
    |
    Jin Beixin (firsekibart)
    1year
    Gensci 048-203: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Jin Beixin (firsekibart)
    1year
    A Bioequivalence Study of Two Different Dosage Form of Genakumab (clinicaltrials.gov)
    P1, N=178, Active, not recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jin Beixin (firsekibart)
    1year
    To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. (clinicaltrials.gov)
    P=N/A, N=221, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Phase classification: P2b --> PN/A | N=30 --> 221 | Trial completion date: Oct 2024 --> Jun 2028 | Trial primary completion date: Jul 2024 --> Mar 2028
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Jin Beixin (firsekibart)